Spirepoint Private Client LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,827 shares of the company's stock after purchasing an additional 3,711 shares during the period. Johnson & Johnson accounts for about 2.2% of Spirepoint Private Client LLC's investment portfolio, making the stock its 6th largest position. Spirepoint Private Client LLC's holdings in Johnson & Johnson were worth $16,721,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in JNJ. Tallon Kerry Patrick acquired a new position in shares of Johnson & Johnson during the 4th quarter worth $290,000. Brighton Jones LLC boosted its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Union Bancaire Privee UBP SA acquired a new position in Johnson & Johnson during the fourth quarter worth $85,886,000. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares in the last quarter. Finally, Legacy Capital Group California Inc. lifted its position in shares of Johnson & Johnson by 1.1% in the fourth quarter. Legacy Capital Group California Inc. now owns 13,566 shares of the company's stock worth $1,962,000 after buying an additional 154 shares during the last quarter. Institutional investors own 69.55% of the company's stock.
Johnson & Johnson Trading Up 0.6%
Johnson & Johnson stock opened at $152.27 on Wednesday. The business has a 50 day moving average price of $153.99 and a two-hundred day moving average price of $153.68. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market cap of $366.36 billion, a price-to-earnings ratio of 16.94, a price-to-earnings-growth ratio of 2.29 and a beta of 0.42.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.
Johnson & Johnson Increases Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.42%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on JNJ shares. Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Finally, Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $170.88.
Check Out Our Latest Analysis on Johnson & Johnson
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
